Contact
Header_1077x260px_About_Profil.jpg

Clinical study shows better clamp quality with Clamp-PID algorithm

Introduction

The glucose clamp is the gold standard for the determination of pharmacokinetic and pharmacodynamic effects of anti-diabetic drugs (e.g. insulins). During a typical glucose clamps the blood glucose (BG) lowering effect is antagonized by infusing glucose at a variable rate, so that BG is "clamped" at a pre-determined target level.  In automated glucose clamps the glucose infusion rate is calculated automatically by a pre-specified algorithm.

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes

Posted by Dr. Carsten Benesch on Mar 17, 2020 5:17:00 PM
dr-carsten-benesch

A novel method to determine the pharmacodynamic onset of action of prandial insulins

Introduction

In order to improve postprandial glycemic control, new insulins are developed, with earlier glucose lowering action by advancing the time to onset of action [1, 2, 3]. The standard for investigating such pharmacodynamic properties of insulin preparations is the euglycemic clamp [4, 5]. The current method established for determining onset of insulin action requests a blood glucose (BG) decrease from baseline (DFB) by at least 5 mg/dl [6, 5]. Unfortunately, DFB under- or overestimates onset of action depending on whether baseline BG trends are decreasing or increasing.

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes

Posted by Dr. Marc Stoffel on Mar 3, 2020 4:56:00 PM
dr-marc-stoffel

Type 1 Diabetes and mild cognitive impairment

Mild cognitive impairment: another complication of Diabetes mellitus type 1?

Diabetes Mellitus (DM) is often considered a risk factor for mild cognitive impairment (MCI) and the association between these pathologies has been well established by several clinical studies [1, 2]. However, this relationship has mainly been studied in patients suffering from Type 2 Diabetes.

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes

Posted by Dr. Grit Andersen on Feb 4, 2020 5:17:00 PM
dr-grit-andersen

Trustworthy AI in healthcare - it's TIME TO DELIVER

In Europe chronic diseases account for 86% of deaths and 77% of disease burden, thereby creating a tremendous challenge on societies. At the same time digitisation is bringing huge technological and cultural opportunities. In healthcare the usage of data-driven forecasts on individual and population health as by integration of artificial intelligence (AI)-enabled algorithms has the potential to revolutionise health protection and chronic care provision while securing the sustainability of healthcare systems.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Jan 7, 2020 5:16:00 PM
prof-dr-freimut-schliess

What news in the treatment of Type 2 diabetes was presented at EASD 2019?

The annual meeting of the European Association for the Study of Diabetes (EASD) took place this year in Barcelona, Spain. The present text offers a selection of topics relevant for the field of type 2 diabetes mellitus (T2DM) discussed during that meeting.

Read More

Topics: The Science behind Diabetes, Treating Diabetes

Posted by Dr. Jorge Arrubla on Oct 17, 2019 5:30:00 PM
dr-jorge-arrubla

iPDM Goes Europe: tangible impact on diabetes patients and care

Treatment inertia calls for an integrated personalized diabetes management: iPDM

Diabetes represents a huge and multidimensional challenge for European societes. It not only leads to premature ageing and frailty but also promotes chronic conditions like cardiovascular disease, blindness, dementia and even cancer. Despite the availability of numerous treatment options treatment inertia is still a common problem: many patents still fail to reach their treatment goals. According to the UK National Diabetes Audit data 2016- 2017, only 30% of people with type 1 diabetes and 67% of people with type 2 diabetes achieved a HbA1c target of not more than 58 mmol/l (7.5%).

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Sep 3, 2019 5:17:00 PM
prof-dr-freimut-schliess

Dual-hormone artificial pancreas systems

Dual-hormone artificial pancreas systems use insulin and glucagon to control glucose in patients with diabetes - a dream is about to come true

Insulin-only closed-loop AP systems hold promise for reducing the burden of diabetes self-management, but there is still potential for improvement regarding both hypoglycaemia and hyperglycaemia. A dual-hormone AP system achieves closed–loop glycaemic control by subcutaneous infusion of insulin and of glucagon in response to glucose values detected by a continuous glucose monitoring device mimicking the physiological pattern of insulin and glucagon secretion of a healthy pancreas more closely than an insulin infusion-only system.

To reverse the insulin action when blood glucose shows a tendency to fall, glucagon is given as mini-boluses to prevent and to treat any imminent hypoglycemia [1]. Glucagon leads to a rapid conversion of hepatic glycogen (the stored form of glucose) into glucose which is then released into the bloodstream. The comprehensive technology of control algorithms and hardware and the development of long-term stable glucagon formulations have so far provided some development challenges.

Read More

Topics: The Science behind Diabetes, Clinical Trials in Diabetes, Treating Diabetes

Posted by Dr. Ulrike Hövelmann on Jul 16, 2019 5:03:00 PM
dr-ulrike-hövelmann

Applications of iontophoresis in studies investigating microvasculature

People suffering from Diabetes Mellitus can develop both macrovascular and microvascular complications. Retinopathy, nephropathy and neuropathy are the main microvascular complications occurring in Diabetes Mellitus. Mechanisms include structural and functional alterations resulting from chronically elevated glucose concentrations. Therefore, assessment of the microvasculature is important for studies investigating new treatment modalities in diabetes.

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes, Clinical Trial Methods

Posted by Dr. Jorge Arrubla on Jun 4, 2019 5:21:00 PM
dr-jorge-arrubla

The ideal basal insulin?

Long-acting insulins have been developed for patients with diabetes to provide a basal insulin cover during the day and night. The first slow-release formulations used protamine and/or zinc to achieve a duration of action up to 16 hours. Since 2000 insulin analogues with different mechanisms of protraction are available and achieve a predictable glucose lowering effect with one daily injection. Currently, ultra-long acting insulin analogues are available that have a duration of action beyond 24 hours. This prolonged duration of action reduces day-to-day variability and offers daily dosing flexibility [1]. What further improvements in basal insulin therapy can be expected in the future and what exactly does the ideal basal insulin look like?

Read More

Topics: Treating Diabetes

Posted by Dr. Eric Zijlstra on May 21, 2019 4:57:00 PM
dr-eric-zijlstra

Profil is co-founder of KomIT

KomIT - the new Center of Competence for Innovative Diabetes Therapy

Profil is co-founder of a new consortium of partners from industry and academia focusing on the development and clinical implementation of new diabetes therapies. 
 

During the next three years KomIT, the new Center of Competence for Innovative Diabetes Therapy, will be established at the German Diabetes Center (DDZ) based on a total funding of about 3.5 Mio Euro. This funding is jointly provided by the Land North Rhine-Westphalia and the European Union. KomIT is coordinated by Professor Michael Roden, the scientific Managing Director of the DDZ.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Svenya Meister on Apr 30, 2019 5:09:00 PM
svenya-meister

Subscribe to our monthly blog updates

Find out more: Glucose Clamp Webinar

Subscribe to Email Updates

Our most popular Posts